Avoid common mistakes on your manuscript.
Correction to: Cancer Chemotherapy and Pharmacology https://doi.org/10.1007/s00280-023-04507-w
The article “A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C”, written by Richard Kim · Alexis D. Leal · Aparna Parikh · David P. Ryan · Shining Wang · Brittany Bahamon ·Neeraj Gupta · Aaron Moss · Joanna Pye · Harry Miao · Haig Inguilizian and James M. Cleary was originally published Online First without Open Access. With the author(s)' decision to opt for Open Choice the copyright of the article changed on 6th March 2023 to © The Author(s) 2023 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Kim, R., Leal, A.D., Parikh, A. et al. Correction to: A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C. Cancer Chemother Pharmacol 91, 301 (2023). https://doi.org/10.1007/s00280-023-04522-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-023-04522-x